- Home
- RPRX
RPRX
Royalty Pharma plc
as 05-20-2024 9:36am EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 12.7B | IPO Year: | 2020 |
| Target Price: | $46.75 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | 3.08% | Dividend Payout Frequency: | Quarterly |
| EPS: | 1.77 | EPS Growth: | 139.19 |
| 52 Week Low/High: | $25.92 - $34.65 | Next Earning Date: | 05-09-2024 |
| Revenue: | $2,238,561,000 | Revenue Growth: | -5.11% |
| Revenue Growth (this year): | 13.74% | Revenue Growth (next year): | 9.41% |
Share on Social Networks:
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RIGGS RORY B | RPRX | Director | Jan 2 '24 | Sell | $28.52 | 235,200 | $6,707,080.80 | 254,899 | SEC Form 4 |
| RIGGS RORY B | RPRX | Director | Jan 2 '24 | Sell | $27.79 | 199,098 | $5,532,276.40 | 55,801 | SEC Form 4 |
| RIGGS RORY B | RPRX | Director | Jan 2 '24 | Sell | $27.55 | 35,702 | $983,504.42 | 20,099 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 27 '23 | Sell | $28.01 | 41,729 | $1,168,754.18 | 2,753,186 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 27 '23 | Sell | $28.20 | 209,863 | $5,918,934.08 | 2,543,323 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 15 '23 | Sell | $28.01 | 10,229 | $286,498.95 | 2,794,915 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 13 '23 | Sell | $28.95 | 307,935 | $8,916,011.58 | 3,169,585 | SEC Form 4 |
| Avara Management Ltd | RPRX | 10% Owner | Dec 13 '23 | Sell | $28.91 | 364,441 | $10,534,276.44 | 2,805,144 | SEC Form 4 |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Royalty Pharma to Present at Upcoming Investor Conferences
Simply Wall St.
8 days ago
Here's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter Results
Simply Wall St.
9 days ago
Only Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) Dividend
GuruFocus.com
10 days ago
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight
Morningstar Research
11 days ago
Analyst Report: Royalty Pharma plc
GlobeNewswire
11 days ago
Royalty Pharma Reports First Quarter 2024 Results
GlobeNewswire
11 days ago
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
Simply Wall St.
16 days ago